4HW7

Crystal structure of FMS kinase domain with a small molecular inhibitor, PLX647-OME


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.220 
  • R-Value Observed: 0.222 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Zhang, C.Ibrahim, P.N.Zhang, J.Burton, E.A.Habets, G.Zhang, Y.Powell, B.West, B.L.Matusow, B.Tsang, G.Shellooe, R.Carias, H.Nguyen, H.Marimuthu, A.Zhang, K.Y.Oh, A.Bremer, R.Hurt, C.R.Artis, D.R.Wu, G.Nespi, M.Spevak, W.Lin, P.Nolop, K.Hirth, P.Tesch, G.H.Bollag, G.

(2013) Proc Natl Acad Sci U S A 110: 5689-5694

  • DOI: 10.1073/pnas.1219457110
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Inflammation and cancer, two therapeutic areas historically addressed by separate drug discovery efforts, are now coupled in treatment approaches by a growing understanding of the dynamic molecular dialogues between immune and cancer cells. Agents th ...

    Inflammation and cancer, two therapeutic areas historically addressed by separate drug discovery efforts, are now coupled in treatment approaches by a growing understanding of the dynamic molecular dialogues between immune and cancer cells. Agents that target specific compartments of the immune system, therefore, not only bring new disease modifying modalities to inflammatory diseases, but also offer a new avenue to cancer therapy by disrupting immune components of the microenvironment that foster tumor growth, progression, immune evasion, and treatment resistance. McDonough feline sarcoma viral (v-fms) oncogene homolog (FMS) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) are two hematopoietic cell surface receptors that regulate the development and function of macrophages and mast cells, respectively. We disclose a highly specific dual FMS and KIT kinase inhibitor developed from a multifaceted chemical scaffold. As expected, this inhibitor blocks the activation of macrophages, osteoclasts, and mast cells controlled by these two receptors. More importantly, the dual FMS and KIT inhibition profile has translated into a combination of benefits in preclinical disease models of inflammation and cancer.


    Organizational Affiliation

    Plexxikon Inc., Berkeley, CA 94710, USA. CZhang@plexxikon.com



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Macrophage colony-stimulating factor 1 receptor
A
343Homo sapiensMutation(s): 3 
Gene Names: CSF1RFMS
EC: 2.7.10.1
Find proteins for P07333 (Homo sapiens)
Go to UniProtKB:  P07333
NIH Common Fund Data Resources
PHAROS  P07333
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
64M
Query on 64M

Download CCD File 
A
5-[(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[4-(trifluoromethyl)benzyl]pyridin-2-amine
C22 H19 F3 N4 O
WLYQGNIWNGFGPH-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
64MIC50 :  62   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 0.267 
  • R-Value Work: 0.220 
  • R-Value Observed: 0.222 
  • Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 62.964α = 90
b = 62.964β = 90
c = 182.78γ = 90
Software Package:
Software NamePurpose
Blu-Icedata collection
MOLREPphasing
PHENIXrefinement
MOSFLMdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2012-11-07 
  • Released Date: 2013-03-27 
  • Deposition Author(s): Zhang, Y., Zhang, C.

Revision History 

  • Version 1.0: 2013-03-27
    Type: Initial release
  • Version 1.1: 2013-04-17
    Changes: Database references